We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

406 hedge funds and large institutions have $17.3B invested in Alexion Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 406 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $149M | Put options by funds: $97.1M

Holders
406
Holders Change
+406
Holders Change %
–
% of All Funds
13.25%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.2%
New
406
Increased
–
Reduced
–
Closed
–
Calls
$149M
Puts
$97.1M
Net Calls
+$51.9M
Net Calls Change
+$51.9M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
326
Paradigm Asset Management
New York
$396K +$413K +4,290 New
WTIM
327
Wilmington Trust Investment Management
Delaware
$387K +$405K +4,200 New
TNBTD
328
Trustmark National Bank Trust Department
Mississippi
$376K +$393K +4,075 New
Luther King Capital Management (LKCM)
329
Luther King Capital Management (LKCM)
Texas
$369K +$385K +4,000 New
PTC
330
Philadelphia Trust Company
Pennsylvania
$369K +$385K +4,000 New
ISL
331
Ingalls & Snyder LLC
New York
$368K +$385K +4,000 New
HHGA
332
Halbert Hargrove Global Advisors
California
$359K +$375K +3,896 New
Nisa Investment Advisors
333
Nisa Investment Advisors
Missouri
$355K +$371K +3,850 New
B
334
Barings
North Carolina
$353K +$369K +3,830 New
Tudor Investment Corp
335
Tudor Investment Corp
Connecticut
$351K +$366K +3,800 New
CC
336
ClearArc Capital
Ohio
$345K +$361K +3,741 New
GMIM
337
General Motors Investment Management
New York
$343K +$358K +3,716 New
CI
338
Conning Inc
Connecticut
$335K +$350K +3,630 New
RCM
339
Reynolds Capital Management
Nevada
$333K +$347K +3,600 New
PGFC
340
Peapack-Gladstone Financial Corp
New Jersey
$312K +$326K +3,383 New
OC
341
Oppenheimer & Co
New York
$303K +$316K +3,283 New
TH
342
Timber Hill
Connecticut
$259K +$271K +2,809 New
NPC
343
National Planning Corporation
California
$258K +$271K +2,807 New
Commonwealth Equity Services
344
Commonwealth Equity Services
Massachusetts
$252K +$263K +2,734 New
Bank of Nova Scotia
345
Bank of Nova Scotia
Ontario, Canada
$249K +$260K +2,699 New
LTFS
346
Ladenburg Thalmann Financial Services
Florida
$243K +$250K +2,596 New
FT
347
Fiduciary Trust
Massachusetts
$231K +$241K +2,500 New
MYAM
348
Meiji Yasuda Asset Management
Japan
$230K +$236K +2,450 New
1IC
349
1919 Investment Counsel
Maryland
$229K +$239K +2,479 New
CB
350
Commerce Bank
Missouri
$226K +$236K +2,452 New
12 13
14
15 16

ALXN Hedge Fund Activity: Q2 2013 in Review

406 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2013, worth a combined $17.3B.

Buyers outnumbered sellers: 406 funds opened new ALXN positions and 0 closed out — a net gain of 406 holders — while 0 added to existing stakes and 0 trimmed.

  • 406 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $17.3B of Alexion Pharmaceuticals stock for Q2 2013.
  • 406 funds opened new Alexion Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +406 holders.

Based on aggregated 13F filings for Q2 2013.